ABBVIE

TRANSCEND CLL 004 study data showed Breyanzi with Imbruvica achieved 86% response rate and 45% complete remission in relapsed/refractory CLL/SLL patients. Breyanzi, first CAR T therapy for CLL, targets unmet need in patients failing BTK and BCL2 inhibitors. Breyanzi sales projected to reach $2.6 billion by 2030.

COVID-19 treatment companies focus on vaccines, antivirals, monoclonal antibodies, and supportive care. Vaccines like Pfizer-BioNTech and Moderna reduce severe cases, while antivirals like Remdesivir and Paxlovid limit viral replication. Monoclonal antibodies like Bamlanivimab offer early intervention. Supportive care remains crucial. Market growth is driven by COVID-19 spread, new variants, and increased demand for effective therapies. Government investments and rapid vaccine advancements accelerate treatment availability. The global pulmonary drug delivery systems market is projected to reach USD 97.8 billion by 2033.

AbbVie's phase 3 TEMPO-2 trial showed tavapadon met primary and secondary endpoints in early Parkinson disease, with significant reductions in MDS-UPDRS Parts II and III scores. AbbVie plans to submit full results for presentation and the new drug application to the FDA in 2025.

BenevolentAI co-founder Kenneth Mulvaney announces restructuring to return to 'techbio' roots, including layoffs and delisting from Euronext Amsterdam. Tasca Therapeutics raises $52M in Series A funding for cancer drug development. Eli Lilly's board approves $15B stock buyback and 15% dividend increase. AbbVie's Parkinson's drug tavapadon succeeds in Phase 3 trial, prompting approval filing plans. Biogen appoints Tim Power as head of investor relations.

The article content provided does not contain any readable text for summarization.

AbbVie's Phase 3 TEMPO-2 trial of tavapadon met primary endpoint with significant improvement in MDS-UPDRS Parts II and III scores at week 26, showing a reduction of -10.3 vs. -1.2 for placebo. Tavapadon, a D1/D5 partial agonist, is under investigation as a once-daily treatment for Parkinson's disease. AbbVie plans to submit an NDA to the FDA in 2025.

Researchers identified 13 proteins predicting brain aging speed; midlife anxiety often precedes dementia; tavapadon improved Parkinson's symptoms; neflamapimod failed in dementia with Lewy bodies; cortical sulcus neurodegeneration linked to CTE; ALS/cancer patients more likely to choose assisted dying; former soccer players at higher dementia risk; diverse brain cells contribute to Alzheimer's neuroinflammation; media highlighted Alzheimer's and Parkinson's stories.

The Parkinson's disease market is expected to grow significantly, reaching USD 6.2 billion by 2034, driven by advancements in diagnostics, disease awareness, and emerging therapies. Key therapies in development include ND0612, tavapadon, P2B001, BIIB122/DNL151, Buntanetap, Solengepras, and Minzasolmin. These therapies aim to improve motor function, manage symptoms, and potentially slow disease progression.

Regeneron's Ordspono shows promise in treating r/r MZL with 77.1% ORR and CR rate, but faces challenges like low long-term adherence and regulatory delays. It received EU approval for r/r FL and DLBCL, but US market adoption is pending confirmatory trials. Competitors like AbbVie and Genmab's Epkinly pose threats with more convenient administration routes.

SetPoint Medical submitted a PMA to FDA for a neuroimmune modulation device to treat RA patients unresponsive to pharmacological treatments. The device uses vagus nerve stimulation to activate anti-inflammatory pathways. Supported by RESET-RA clinical study data, it aims to provide a safe and effective alternative to current RA care. The neuromodulation market is expanding, with SetPoint targeting indications beyond RA, including RRMS.